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ation between PRU quintiles and mortality.Table. Event Rates Among Quintiles of PRU
1-year event
rates
Quintile
1
Quintile
2
Quintile
3
Quintile
4
Quintile
5
p(<95)
(95-
159)
(160-
215)
(216-
275) (>275)
Def/prob ST 0.49% 0.43% 0.79% 1.13% 1.33% 0.01
Major Bleeding 8.17% 5.81% 5.74% 5.27% 5.67% <0.01
Mortality 1.52% 1.55% 1.72% 2.37% 2.39% 0.15
Baseline
Characteristics CCB (n=2437) No CCB (n=6146) p-value
Mean age, years 65.510.7 62.910.8 <0.0001
Diabetes 39.8% 29.5% <0.0001
Hypertension 92.3% 74.6% <0.0001
Hyperlipidemia 79.6% 72.2% <0.0001
Acute Coronary
Syndrome
49.0% 52.7% 0.002
VerifyNow P2y12
Mean PRU 199.498.0 183.495.9 <0.0001
PRU > 208 47.9% 40.7% <0.0001
%inhibition 37.2% 41.1% <0.0001
1-Year Follow-up
(out of hospital)
CCB (n[1771) No CCB
(n[6811)
Death 3.2% 1.6% <0.0001
MI 2.5% 1.6% 0.01
MACE 3.4% 2.4% 0.01
Stent thrombosis
(deﬁnite/probable)
0.99% 0.66% 0.16
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SConclusions: In this large observational study, while HPR was associated with ST in
a graded fashion, bleeding risk was conﬁned to pts in the lowest PRU quintile
(PRU<95). There was no demonstrable threshold effect for HPR and mortality,
perhaps due to the offsetting impact of bleeding and ischemic outcomes.
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Background: High platelet reactivity (HPR) is associated with poor prognosis in coro-
nary artery disease. Recently PLATO subgroup analysis showed that ticagrelor is better
clinical outcome than the clopidogrel,whichwas relatedwith lowHPR.Alsomany studies
reported that adjunctive cilostazol to dual antiplatelet therapy (DAPT) (so called triple
antiplatelet therapy; TAT) is better clinical outcome than DAPT, which was associated
with a greater antiplatelet effect at 30 days. Thus, this study was designed to compare the
effect of ticagrelor and TAT on platelet reactivity with PRU and ARU values.
Methods: This study was composed of total 65 patients underwent the coronary stenting.
All patients received a 600-mg loading dose of clopidogrel or a 180-mg loading dose of
ticagrelor and concomitant aspirin therapy. After patients underwent coronary stenting,
theywere nonrandomly assigned to 1 of 4 groups:DAPT group (n¼15), clopidogrel of 75
mg daily; ticagrelor group (n¼20), ticagrelor of 180 mg daily; TAT group (n¼15),
adjunctive cilostazol of 100mg twice daily to clopidogrel of 75mg daily; and triple switch
group (n¼15), switch of ticagrelor to TAT since 3rd day. The platelet reactivity was
assessed by ARU and PRU values at day 2 and day 7, respectively.
Results: The average PRU value was lower in ticagrelor and TAT group than DAPT
throughout the study period but the average ARU value did not differ among the 4
groups. The 2nd day average ARU was lower in the TAT group than ticagrelor group
(405 vs. 510, p<0.01) and there was no signiﬁcant difference on 7th day average ARU
value. In ticagrelor group, 7th day average ARU is lower than 2th day ARU (458 vs.
510, p<0.05). Compared with TAT group, ticagrelor group had signiﬁcantly lower PRU
level at 2nd day and 7th day, respectively (91 vs. 162, p<0.05, 50 vs. 163, p<0.01). The
2nd day average PRU value of triple switch group was 70 which was similar to PRU of
ticagrelor group and 7th day average PRU (151) was similar to that of TAT group.
Conclusions: The ticagrelor and TAT therapy had the lower PRU level than DAPT
and especially, ticagrelor showed the lowest incidence of HPR. This indicates that
ticagrelor is more effective in HPR treatment than TAT.
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Background: In patients undergoing PCI for STEMI/NSTEMI, a loading dose (LD)
of the new potent P2Y12 inhibitors, thanks to their early onset of platelet inhibition,
can be administered immediately after the diagnostic coronary angiography. However,
there are no data about the level of platelet inhibition they provide during and
immediately after the PCI with this timing of administration. We sought to assess and
compare the action of prasugrel, ticagrelor and clopidogrel during and immediately
after the PCI for STEMI/NSTEMI when administered with this speciﬁc timing.
Methods: Seventy-two patients with STEMI/NSTEMI undergoing urgent PCI with
heparin monotherapy were randomized after the coronary angiogram to receive 60 mg
prasugrel LD (n 24) or ticagrelor 180 mg (n 24) or clopidogrel 600 mg (n 24).
Residual platelet reactivity was assessed with VerifyNow at baseline, 30 min and 120
min after the LD. A 24 h platelet reactivity assessment with Light Transmission
Aggregometry (LTA) was also performed.
Results: Platelet reactivity units (PRU) 30 min after the LDwere 305 (70), 286 (59)
and 280 (70) in the prasugrel, ticagrelor and clopidogrel group, respectively (p¼NS).
PRU 120 min after the LD were 220 (100), 210 (88) and 163 (101), respectivelyJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr(overall p 0.1). At 120 min PRU post hoc analysis only clopidogrel Vs ticagrelor were
signiﬁcantly different (p¼ 0.03). Furthermore, high residual platelet reactivity (HRPR)
(PRU> 240) was found in 52%, 28% and 58% of patient in the prasugrel, ticagrelor and
clopidogrel group, respectively (p¼ 0.12). No case of HRPR (deﬁned as LTA assessed
residual platelet activity> 65%) were found in the prasugrel and ticagrelor group while
55% of patients showed HRPR in the clopidogrel group (p< 0.01). At multivariate
analysis no independent predictors of HRPR at 120 min were found.
Conclusions: None of the drugs studied achieved an effective platelet inhibition
during the PCI when administered immediately after the coronary angiogram in
patients with STEMI/NSTEMI. At 120 min only ticagrelor achieved a signiﬁcantly
higher inhibition of platelet reactivity when compared to clopidogrel. A high
percentage of HRPR both at 30 min and 120 min was present in all groups.
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Background: Many patients with coronary artery disease receive concomitant treat-
ment with clopidogrel and calcium channel blockers (CCB). Prior small studies have
raised concerns regarding the effect of CCB on clopidogrel-related platelet reactivity
and its clinical signiﬁcance. We examined this relationship in the large scale
Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES)
registry.
Methods: A total of 8,583 patients had P2Y12 platelet reactivity testing using the
VerifyNow point-of-care assay after successful, non-complicated PCI with DES
implantation. All patients were treated with aspirin and clopidogrel, and were followed
for 1 year. CCB were prescribed at the discretion of treating physicians.
Results: At the time of the post-procedure P2Y12 test, 2437 (28.4%) pts were on
CCB, and 6146 (71.6%) were not. Major baseline characteristics, P2Y12 results and
1-year follow-up events are summarized in the Table. The use of CCB was an
independent predictor of higher platelet reactivity units (PRU) in a linear regression
model (p<0.0001), and was independently associated with high platelet reactivity as
deﬁned as PRU >208 (OR 1.16, p¼0.014). At discharge, 1771 (20.6%) pts were
prescribed CCB, and 6811 (79.4%) were not. In propensity-stratiﬁed proportional
hazards regression models, the use of CCB was not independently associated with
adverse outcomes.acts/POSTER/Antiplatelets and Antithrombins B49
Baseline
Characteristics
Current Smoker
(n=1939)
Not Current
Smoker
(n=6644) p-value
Mean age, years 59.6  9.6 65.6  10.4 <0.0001
BMI 28.7  5.4 29.7  5.8 <0.0001
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SConclusions: In patients on clopidogrel after DES, the concomitant administration of
CCB was associated with reduced platelet inhibition and increased post discharge
adverse events. However, CCB were not associated with adverse clinical events by
multivariable analysis, suggesting confounding by comorbidities and presenting
characteristics. Thus, CCB may be used as indicated in patients on clopidogrel after
DES.
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Background: In the ADAPT-DES study, clopidogrel hyporesponsiveness was
strongly related to the 1-year incidence of stent thrombosis and of myocardial
infarction after drug-eluting stents, was inversely related to major bleeding, and was
unrelated to mortality.
Methods: The impact of clopidogrel hyporesponsiveness may differ between stable
angina (SAP) and acute coronary syndromes (ACS). We addressed this issue in
a secondary analysis of ADAPT-DES.
Results: Out of the 8449 patients, 4101 (49%) presented with SAP. At 1-year, the
incidences in SAP vs. ACS were 0.5% vs. 1.1% for stent thrombosis (P<0.001), 7.5%
vs. 4.6% for bleeding (P<0.001), 2.7% vs. 3.5% for myocardial infarction (P¼0.057)
and 1.8% vs.1.9% for all-cause death (P¼0.60). In SAP, the relation of clopidogrel
hyporesponsiveness to stent thrombosis (adjusted HR 1.44 [0.53, 3.88]; P ¼ 0.47),
myocardial infarction (1.54 [1.02, 2.32], P¼0.038), bleeding (0.69 [0.54,0.90];
P¼0.005) and death (1.40 [0.83,2.34]; P¼0.21) was consistent with that in the entire
study. Due to the difference in event rates, the absolute difference in the incidence of
stent thrombosis according to clopidogrel responder status was substantially smaller in
SAP compared with ACS, whereas that in bleeding was substantially larger (Figure).
Conclusions: In SAP, therapies aimed at correction of clopidogrel hyporesponsive-
ness for prevention of stent thrombosis may cause a disproportionate increase in
bleeding.B50 JACC Vol 62/18/Suppl B j October 27–NovemTCT-157
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Background: In prior studies non-smokers have been reported to have reduced
clinical beneﬁt of clopidogrel treatment as compared to smokers. This new "smoker's
paradox" has been explained by the increase in the production of clopidogrel's active
metabolite in smokers. We examined this relationship in the large scale Assessment of
Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
Methods: Patients had P2Y12 platelet reactivity testing using the VerifyNow point-
of-care assay after successful, non-complicated PCI with DES implantation. All
patients were treated with aspirin and clopidogrel, and were followed for 1 year.
Current smoking status was deﬁned as active smoking within 1 month prior to
enrollment.
Results: Of the 8,583 patients enrolled, 1,939 (22.6%) pts were current smokers and
6,644 (77.4%) were not. Major baseline characteristics, P2Y12 results and 1-year
events are summarized in the Table. By multivariable analysis, current smoking status
was inversely associated with platelet reactivity (p¼0.0002). In propensity-stratiﬁed
proportional hazards regression models, current smoking was independently associ-
ated with 1-year all-cause mortality (HR [95%CI ¼ [1.54 [1.00, 2.38], p¼0.048), but
not with stent thrombosis (HR [95%CI ¼ [1.11 [0.62, 2.00], p¼0.72) or major
bleeding (HR [95%CI ¼ [1.10 [0.86, 1.41], p¼0.43).Diabetes 25.0% 34.6% <0.0001
Acute coronary
syndrome
65.5% 47.6% <0.0001
VerifyNow P2Y12
Mean PRU 172.0  94.2 192.6  97.0 <0.0001
PRU > 208 36.9% 44.5% <0.0001
%inhibition 41.8  29.2 39.5  27.9 0.0023
1-Year Follow-up
Death 1.7% 2.0% 0.46
MI 3.5% 3.1% 0.40
MACE 6.5% 6.9% 0.52
Stent thrombosis
(deﬁnite/probable)
1.6% 1.4% 0.55
Major bleeding 4.9% 6.6% 0.0075Conclusions: Current smokers treated with clopidogrel after non-complicated PCI
have greater levels of platelet inhibition compared with non-smokers. However, after
adjustment for differences in baseline characteristics, smoking status was indepen-
dently associated with mortality at 1 year. This analysis does not support the existence
of clopidogrel-related "smoker's paradox".ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
